WASHINGTON — The government will allow some private Medicare plans to be more discerning about how they cover prescription drugs, the Trump administration announced in a memo Tuesday.

Specifically, Medicare Advantage plans — private plan alternatives to Medicare that cover about 19 million beneficiaries across the country — will be allowed to require patients who need a costly physician-administered drug, like most chemotherapy, to first use cheaper drugs and see if they work before moving to more expensive drugs.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy